Markets

Pyxis Oncology Appoint Thomas Civik Chairman, CEO, Effective Sept. 4

Sep 8, 2026 · 07:32 AM ET· updated 1h ago

Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, announced today that its Board of Directors has appointed Thomas Civik as Chief

Why It Matters

Pyxis Oncology picked a new leader, Thomas Civik, to run the company starting September 4th. When a company gets a new top boss, watch to see if the team starts making faster progress on their cancer medicine projects.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

PYXS3.94

+0.04 (+1.16%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.